Couriers for Research Peptides to Argentina

Three international couriers have regular coverage for this type of shipment: DHL Express, FedEx Express, and UPS. All three transport lyophilised laboratory material to Argentina when the shipment is declared correctly as laboratory reference material. The choice of courier matters less than the documentation that accompanies the package.

DHL, FedEx, and UPS: carriers with established networks

DHL Express, FedEx Express, and UPS operate networks covering Argentina with entry through Ezeiza International Airport. All three have experience handling scientific material and accept laboratory cargo when the customs declaration is consistent with what the package contains.

DHL Express has the broadest presence for precision shipments from the United States and Europe into Latin America. FedEx Express operates life-sciences divisions with coverage from North American hubs. UPS covers the segment through its international priority freight network.

None of the three operates as a pharmaceutical distributor. The correct framing for research peptides is laboratory reference material or research-grade chemical reagent — never medication, never supplement. That distinction is what determines customs treatment once a package arrives at Ezeiza.

Specialised consolidation services that handle laboratory materials between the United States and Argentina also exist. For shipments combining multiple compounds or requiring particular handling conditions, these services can offer greater logistical flexibility than high-volume carriers. In every case the customs process is the same: what determines the outcome is the file, not the carrier.

The documentation that decides whether a shipment clears

AFIP, Argentina's customs authority, evaluates each shipment against its declared documentation. A package without the correct declaration can be held or reclassified regardless of which courier transported it.

The documents a research peptide shipment needs to enter Argentina correctly are:

• Commercial or proforma invoice with the exact compound name, lot number, quantity in milligrams, and an explicit declaration of research use.
• Certificate of Analysis (CoA) from an independent laboratory, with a verifiable task number. PeptoClinic publishes its reports on the quality page.
• Safety Data Sheet (SDS) for the compound, listing physicochemical properties and hazard classification.
• End-use declaration stating that the material is intended exclusively for laboratory research and not for human or veterinary use.

The customs classifier verifies the consistency of these four documents against each other. A CoA from Janoshik Analytical that lists the same lot number as the invoice, for a compound declared as laboratory reference material, forms an evidence chain without gaps. A package whose invoice reads "research peptide" but whose labelling suggests personal use is a contradiction that can stop the shipment.

How Argentina classifies peptides at customs

Argentina uses the Common Nomenclature of Mercosur (NCM) to classify imports. The tariff position depends on the chemical nature of the compound and on how its end use is declared.

Chemically synthesised peptides imported as reference substances or laboratory reagents receive different treatment from the rules governing registered medicines before ANMAT. A registered medicine requires sanitary registration prior to entry; a laboratory reference material does not, but it must be declared under the NCM position that corresponds to organic compounds for analytical or research use.

The most common error is declaring the material under a position that triggers pharmaceutical controls, or with a description vague enough that customs reclassifies it on its own terms. In both cases the result is a delay or a hold that requires additional documentation to resolve.

PeptoClinic prepares the import file for each shipment to Argentina with the classification that applies to laboratory reference material. Details of the process are on the shipping page.

Lyophilised powder and the cold chain

The physical format of the compound affects shipping logistics. A peptide in lyophilised powder form is significantly more stable in transit than a reconstituted solution. PeptoClinic supplies compounds in lyophilised powder vials, which reduces dependence on a strict cold chain during standard transit.

This does not mean lyophilised powder is insensitive to environmental conditions. Vials must be kept away from moisture and direct light. For transits involving uncontrolled ambient conditions or extended layovers, packaging with refrigerant gel remains standard practice in the sector.

International couriers offer special-handling categories for laboratory materials: temperature-controlled service, non-hazardous classification, and sealed secondary packaging. The shipper is responsible for specifying the required handling conditions at the time of dispatch, and that information must appear on the air waybill alongside the rest of the documentation.

What happens if customs holds the shipment

A hold is not uncommon for laboratory material shipments, particularly when documentation has inconsistencies or when the classifier does not recognise the compound. The standard procedure is for the recipient or a designated customs agent to submit supplementary documentation: the original CoA, the invoice, and the end-use declaration. In some cases a technical consultation with a professional registered before AFIP can move the process forward.

The difference between a shipment that clears promptly and one that sits in review is almost always in the original file, not in the subsequent appeal. A package that arrives with coherent documentation from the point of origin has the most direct path.

Compounds such as retatrutide and BPC-157 are supplied to Argentina with the import file prepared. For questions about the documentation applicable to a specific compound, contact PeptoClinic at [email protected] before the shipment leaves.

For laboratory research only

All material supplied by PeptoClinic is for exclusive use in in vitro and laboratory research. It is not a medicine, not a supplement, and not approved for human or veterinary use. No regulatory authority — ANMAT, the FDA, or any equivalent — has evaluated these compounds for therapeutic use in this context.

PeptoClinic is not a pharmacy, a clinic, or a source of guidance on dosing or administration. Enquiries about human-use protocols are not attended to. The applicable regulatory framing is that of reference material for research use.